Welcome to our dedicated page for Aardvark Therapeutics news (Ticker: AARD), a resource for investors and traders seeking the latest updates and insights on Aardvark Therapeutics stock.
Aardvark Therapeutics (AARD) is a clinical-stage biopharmaceutical company pioneering novel therapies for metabolic diseases through targeted activation of gut-based receptors. This page serves as the definitive source for verified news and official announcements related to their research programs, clinical developments, and corporate milestones.
Investors and researchers will find timely updates on clinical trial progress, regulatory designations, and scientific partnerships, including developments in their lead candidate ARD-101 for hyperphagia management. The curated news collection provides essential context about their unique approach to appetite regulation through TAS2R-targeted therapeutics.
All content undergoes rigorous verification to ensure accuracy, with focus areas including trial phase advancements, peer-reviewed research citations, and strategic collaborations. Regular updates reflect the company's progress in addressing rare metabolic disorders while maintaining compliance with financial disclosure standards.
Bookmark this page for direct access to primary source updates about Aardvark's innovative pipeline and regulatory milestones. For comprehensive tracking of this clinical-stage biopharma's progress, consider subscribing to Stock Titan's news alerts.
Aardvark Therapeutics (Nasdaq: AARD) presented preclinical and clinical data at ObesityWeek 2025 supporting its metabolic obesity programs ARD-201, ARD-101 and WE-868.
Key highlights: ARD-201 (fixed-dose ARD-101 + sitagliptin) reduced fat mass comparable to high-dose tirzepatide while preserving lean mass, delivered glucose control comparable to high-dose tirzepatide, and previously showed ~19% weight reduction after 30 days and ~30% weight loss when combined with low-dose tirzepatide. ARD-101 showed signals of weight control, reduced hunger, and favorable tolerability in a Phase 2a study. WE-868 showed dose-dependent prevention of diet-induced weight gain in preclinical models.
Aardvark Therapeutics (Nasdaq: AARD) announced inducement equity option grants for new hires under Nasdaq Listing Rule 5635(c)(4).
The company granted options on three dates: Oct 20, 2025 (23,602 shares at $12.28), Oct 28, 2025 (aggregate 49,849 shares at $12.00), and Nov 3, 2025 (14,766 shares at $10.39), totaling 88,217 option shares. Each option’s exercise price equals the closing stock price on the grant date. Options vest over four years with 25% at the one-year anniversary and monthly vesting thereafter, subject to continued employment.
Aardvark Therapeutics (Nasdaq: AARD) will present at two investor conferences in November 2025: the Stifel 2025 Healthcare Conference in New York on Tuesday, November 11 at 4:40 p.m. ET, and the TD Cowen Treatment Advancements in Obesity & Related Disorders Summit (virtual) on Monday, November 24 at 3:00 p.m. ET. Live webcasts of both presentations will be available via the company investor website and archived for approximately one month after each presentation.
Aardvark Therapeutics (Nasdaq: AARD) will present clinical and preclinical data at ObesityWeek 2025 in Atlanta on November 4-7, 2025. Two poster presentations on Tuesday, November 4, 2025 at 7:30 p.m. ET include:
- ARD-101 (TAS2R pan-agonist) — data showing attenuation of weight gain in mice and reduced hunger in adults with obesity; presenter: Timothy Kieffer, Ph.D., CSO.
- WE-868 (isoflavonoid modulator of oxidative metabolism) — therapeutic potential in obesity and diabetes; presenter: Tien Lee, M.D., CEO.
Aardvark will host an investor webinar on Wednesday, November 5, 2025 from 5:00–7:00 p.m. ET to review ARD-101, ARD-201 and WE-868 data, include key opinion leaders, and discuss ARD-101 in Prader-Willi Syndrome with PWS Association USA. The live webcast and an archived recording (available for ~one month) will be on the company website under the Investors tab.
Aardvark Therapeutics (Nasdaq: AARD) announced FDA alignment on a protocol amendment to its Phase 3 HERO trial of ARD-101 for hyperphagia in Prader-Willi syndrome (PWS).
The amendment lowers minimum enrollment age from 13 to 10 years, broadening the eligible patient population. Management cited community support and historical data suggesting younger patients may benefit more from early intervention. The company reaffirmed a planned topline data readout in Q3 2026.
Aardvark Therapeutics (NASDAQ:AARD), a clinical-stage biopharmaceutical company, will present at the Stifel 2025 Virtual Cardiometabolic Forum on September 30, 2025 at 9:00 a.m. Eastern time. The company specializes in developing novel, small-molecule therapeutics that activate innate homeostatic pathways for treating metabolic diseases.
Investors can access the live webcast presentation through Aardvark's website at www.aardvarktherapeutics.com in the investors section. A recording will remain available for approximately one month after the presentation.
Aardvark Therapeutics (NASDAQ:AARD), a clinical-stage biopharmaceutical company developing small-molecule therapeutics for metabolic diseases, has granted inducement stock options to two new employees. The awards, issued on August 28, 2025, consist of options to purchase 20,013 shares of common stock at an exercise price of $8.49 per share.
The options were granted under the company's 2025 Inducement Equity Incentive Plan and will vest over four years, with 25% vesting after one year and the remaining vesting monthly at 1/48th of the total shares, contingent on continued employment.
Aardvark Therapeutics (NASDAQ:AARD), a clinical-stage biopharmaceutical company, will present at three major healthcare investor conferences in September 2025. The company, which focuses on developing novel small-molecule therapeutics for metabolic diseases, will participate in the Cantor Fitzgerald Global Healthcare Conference (September 3), Morgan Stanley Global Healthcare Conference (September 8), and H.C. Wainwright Global Investment Conference (September 10).
All presentations will be available via live webcast on the company's website, with recordings accessible for approximately one month afterward.
Aardvark Therapeutics (NASDAQ:AARD) reported Q2 2025 financial results and provided significant pipeline updates. The company ended Q2 with $141.8 million in cash, supporting operations into 2027. Net loss increased to $14.4 million from $5.4 million year-over-year.
Key developments include plans to expand the Phase 3 HERO trial of ARD-101 for Prader-Willi Syndrome to include patients under 13 years old. New preclinical data for ARD-201 showed promising results in preventing weight rebound after GLP-1RA discontinuation, leading to two new Phase 2 trials: POWER and STRENGTH, replacing the previously planned EMPOWER trial.
The company strengthened its leadership team with strategic appointments across scientific, commercial, regulatory, and legal functions.
Aardvark Therapeutics (NASDAQ:AARD) has announced promising preclinical data for ARD-201, its novel obesity treatment candidate. In diet-induced obesity (DIO) mouse studies, ARD-201 demonstrated 19% body weight reduction after 30 days as a monotherapy. The oral treatment showed significant potential in three key areas: preventing weight regain after GLP-1RA discontinuation, standalone weight loss therapy, and enhanced efficacy when combined with low-dose tirzepatide.
The company plans to advance ARD-201 into two Phase 2 trials: The POWER trial (2H 2025) will evaluate weight maintenance after GLP-1RA discontinuation, while the STRENGTH trial (1H 2026) will assess ARD-201's effectiveness alone and in combination with GLP-1RA therapy. These trials replace the previously planned EMPOWER trial.
FAQ
What is the current stock price of Aardvark Therapeutics (AARD)?
What is the market cap of Aardvark Therapeutics (AARD)?
